293 related articles for article (PubMed ID: 31100240)
1. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.
Sumanasuriya S; Omlin A; Armstrong A; Attard G; Chi KN; Bevan CL; Shibakawa A; IJzerman MJ; De Laere B; Lolkema M; Lorente D; Luo J; Mehra N; Olmos D; Scher H; Soule H; Stoecklein NH; Terstappen LWMM; Waugh D; de Bono JS
Eur Urol Oncol; 2018 Jun; 1(2):151-159. PubMed ID: 31100240
[TBL] [Abstract][Full Text] [Related]
2. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
[TBL] [Abstract][Full Text] [Related]
3. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen S; Attard G; Beer TM; Beltran H; Bossi A; Bristow R; Carver B; Castellano D; Chung BH; Clarke N; Daugaard G; Davis ID; de Bono J; Borges Dos Reis R; Drake CG; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng F; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Higano CS; James N; Kantoff P; Kellokumpu-Lehtinen PL; Khauli RB; Kramer G; Logothetis C; Maluf F; Morgans AK; Morris MJ; Mottet N; Murthy V; Oh W; Ost P; Padhani AR; Parker C; Pritchard CC; Roach M; Rubin MA; Ryan C; Saad F; Sartor O; Scher H; Sella A; Shore N; Smith M; Soule H; Sternberg CN; Suzuki H; Sweeney C; Sydes MR; Tannock I; Tombal B; Valdagni R; Wiegel T; Omlin A
Eur Urol; 2018 Feb; 73(2):178-211. PubMed ID: 28655541
[TBL] [Abstract][Full Text] [Related]
4. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Gillessen S; Armstrong A; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Bulbul M; Caffo O; Chi KN; Clarke CS; Clarke N; Davis ID; de Bono JS; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; George D; Gleave M; Halabi S; Heinrich D; Higano C; Hofman MS; Hussain M; James N; Jones R; Kanesvaran R; Khauli RB; Klotz L; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Skoneczna I; Small E; Smith M; Soule H; Spratt DE; Sternberg CN; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tilki D; Tombal B; Türkeri L; Uemura H; Uemura H; van Oort I; Yamoah K; Ye D; Zapatero A; Omlin A
Eur Urol; 2022 Jul; 82(1):115-141. PubMed ID: 35450732
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
6. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017.
Saad M; Alip A; Lim J; Abdullah MM; Chong FLT; Chua CB; Ismail F; Khong RK; Lim CS; Loh CS; Malek R; Mohd Ghani KA; Md Noor I; Md Yusoff NA; Nasuha NA; Razack A; Soo Hoo HF; Sundram M; Tan HM; Thiagarajan M; Teh GC; Voon PJ; Ong TA
BJU Int; 2019 Sep; 124(3):373-382. PubMed ID: 31077523
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
Kretschmer A; Tilki D
Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
[TBL] [Abstract][Full Text] [Related]
10. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.
Elghazaly H; Mottet N; Garcia J; Oudard S; Roach M; Abbou C; Merseburger A; Emara A; Shehata S; Tawfik H; Khorshid O; Selim A; Assem A; Abdelkarim K; Ezz El-Arab L; Bazarbashi S; Omar A; Elwakil H; Elashry M; Abou ElFotouh M; Osman T; Ezz El Din M
World J Urol; 2021 May; 39(5):1421-1429. PubMed ID: 32643031
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer.
Gorin MA; Verdone JE; van der Toom E; Bivalacqua TJ; Allaf ME; Pienta KJ
Nat Rev Urol; 2017 Feb; 14(2):90-97. PubMed ID: 27872478
[TBL] [Abstract][Full Text] [Related]
12. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
[TBL] [Abstract][Full Text] [Related]
13. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.
Bruinsma SM; Roobol MJ; Carroll PR; Klotz L; Pickles T; Moore CM; Gnanapragasam VJ; Villers A; Rannikko A; Valdagni R; Frydenberg M; Kakehi Y; Filson CP; Bangma CH;
Nat Rev Urol; 2017 May; 14(5):312-322. PubMed ID: 28290462
[TBL] [Abstract][Full Text] [Related]
14. Consensus on biomarkers for neuroendocrine tumour disease.
Oberg K; Modlin IM; De Herder W; Pavel M; Klimstra D; Frilling A; Metz DC; Heaney A; Kwekkeboom D; Strosberg J; Meyer T; Moss SF; Washington K; Wolin E; Liu E; Goldenring J
Lancet Oncol; 2015 Sep; 16(9):e435-e446. PubMed ID: 26370353
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.
Khauli R; Ferrigno R; Guimarães G; Bulbulan M; Uson Junior PLS; Salvajoli B; Palhares DMF; Racy D; Gil E; de Arruda FF; Lemos GC; Carvalhal GF; de Carvalho IT; Martins IAF; Gimpel IFP; Salvajoli JV; Chambo JL; Pontes J; Filho LAR; Nogueira L; Freitas MRP; Wroclawski M; Arap MA; Sadi MV; Coelho R; Gadia R; Roja RAL; Hanriot RM; Baroni R; Zequi S; Nahas WC; Alfer W; Maluf FC
JCO Glob Oncol; 2021 Apr; 7():530-537. PubMed ID: 33856890
[TBL] [Abstract][Full Text] [Related]
16. Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies.
Constâncio V; Barros-Silva D; Jerónimo C; Henrique R
Expert Rev Mol Diagn; 2019 May; 19(5):367-375. PubMed ID: 30961397
[TBL] [Abstract][Full Text] [Related]
17. Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
Poon DM; Chan CK; Chan TW; Cheung FY; Kwong PW; Lee EK; Leung AK; Leung SY; Ma WK; So HS; Tam PC; Ho LY
BJU Int; 2018 May; 121(5):703-715. PubMed ID: 29211320
[TBL] [Abstract][Full Text] [Related]
18. The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
He WS; Bishop KS
Expert Rev Mol Diagn; 2016 Aug; 16(8):839-52. PubMed ID: 27254598
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
Parimi S; Ko JJ
Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer and liquid biopsies: Clinical applications and challenges.
Urabe F; Sumiyoshi T; Tashiro K; Goto T; Kimura T; Kobayashi T
Int J Urol; 2024 Jun; 31(6):617-626. PubMed ID: 38551314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
